BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Relutrigine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Relutrigine\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07010471-8983@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relutrigine: Phase 3 readout est. (NCT07010471)
DESCRIPTION:Relutrigine\, phase 3\, Epilepsy.\nStudy: A Clinical Trial for 
 Participants With DEE to Assess Efficacy\, Safety\, Tolerability\, and PK 
 of Relutrigine\nEstimated primary completion: December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/relutrigine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07010471
URL:https://assetmemo.bio/drug/relutrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
